Q2 EPS Forecast for Denali Therapeutics Decreased by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at Zacks Research lowered their Q2 2026 EPS estimates for Denali Therapeutics in a report released on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the company will post earnings of ($0.75) per share for the quarter, down from their prior forecast of ($0.74). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.54) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q3 2026 earnings at ($0.73) EPS and FY2026 earnings at ($2.90) EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. The business’s revenue for the quarter was down 99.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.30 earnings per share.

Several other research analysts have also commented on the company. Wedbush reduced their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, September 4th. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Citigroup lifted their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.22.

Denali Therapeutics Stock Down 1.1 %

DNLI opened at $26.15 on Friday. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $32.13. The stock’s fifty day moving average is $27.10 and its two-hundred day moving average is $22.78. The company has a market capitalization of $3.73 billion, a P/E ratio of -27.24 and a beta of 1.38.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. Fisher Asset Management LLC purchased a new stake in Denali Therapeutics in the fourth quarter valued at $59,000. Vanguard Group Inc. boosted its stake in shares of Denali Therapeutics by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 10,834,483 shares of the company’s stock worth $232,508,000 after buying an additional 236,702 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the period. Wasatch Advisors LP raised its position in Denali Therapeutics by 28.9% during the first quarter. Wasatch Advisors LP now owns 402,670 shares of the company’s stock valued at $8,263,000 after acquiring an additional 90,369 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Denali Therapeutics in the first quarter valued at approximately $147,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.